| 前收市價 | 0.4630 |
| 開市 | 0.4700 |
| 買盤 | 0.4647 x 300 |
| 賣出價 | 0.4755 x 300 |
| 今日波幅 | 0.4600 - 0.4789 |
| 52 週波幅 | 0.4600 - 4.2980 |
| 成交量 | |
| 平均成交量 | 680,101 |
| 市值 | 18.059M |
| Beta 值 (5 年，每月) | 2.91 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.9700 |
| 業績公佈日 | 2024年11月07日 - 2024年11月11日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 2.75 |
ZacksBiotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
Novavax and Alnylam are in the spotlight following drug approval and regulatory updates, respectively.
Barrons.comAlzheimer’s Trial Failure Sends Athira Stock Down 75%
Athira’s experimental drug fosgonimeton failed to slow cognitive decline. The biotech firm says it’s not giving up.
ZacksATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.
